Search research articles
Contact Us
Filters
Showing results (71-80 of 128) with videos related to
Page
of 13
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
October 30, 2023
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B
Robert Klamroth, Ashley Bonner, Keith Gomez, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
April 10, 2014
Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement
A G Lau, J Sun, W B Hannah, et al.
Blood
|
April 24, 2016
Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice
Brian Cooley, William Funkhouser, Dougald Monroe, et al.
Cell Reports
|
May 3, 2018
Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX
Suvasini Ramaswamy, Nina Tonnu, Tushar Menon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 15, 2013
Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice
Thipparat Suwanmanee, Genlin Hu, Tong Gui, et al.
Thrombosis Research
|
May 11, 2007
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice
Tong Gui, Adili Reheman, William K Funkhouser, et al.
Gene Therapy
|
June 24, 2011
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia
C Li, N Narkbunnam, R J Samulski, et al.
American Journal of Hematology
|
March 12, 2014
National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting
J Michael Soucie, Connie H Miller, Fiona M Kelly, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 11, 2024
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy
Robbin Itzler, Tyler W Buckner, Frank W G Leebeek, et al.
Plos One
|
February 2, 2023
Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster
Aida Kalantari, Michael J James, Lauren A Renaud, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 128) with videos related to
Sort By:
Page
of 13
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
October 30, 2023
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B
Robert Klamroth, Ashley Bonner, Keith Gomez, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
April 10, 2014
Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement
A G Lau, J Sun, W B Hannah, et al.
Blood
|
April 24, 2016
Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice
Brian Cooley, William Funkhouser, Dougald Monroe, et al.
Cell Reports
|
May 3, 2018
Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX
Suvasini Ramaswamy, Nina Tonnu, Tushar Menon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 15, 2013
Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice
Thipparat Suwanmanee, Genlin Hu, Tong Gui, et al.
Thrombosis Research
|
May 11, 2007
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice
Tong Gui, Adili Reheman, William K Funkhouser, et al.
Gene Therapy
|
June 24, 2011
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia
C Li, N Narkbunnam, R J Samulski, et al.
American Journal of Hematology
|
March 12, 2014
National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting
J Michael Soucie, Connie H Miller, Fiona M Kelly, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
March 11, 2024
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy
Robbin Itzler, Tyler W Buckner, Frank W G Leebeek, et al.
Plos One
|
February 2, 2023
Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster
Aida Kalantari, Michael J James, Lauren A Renaud, et al.
Page
of 13